MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
AVITA Medical EBITDA 2011-2026 | RCEL
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AVITA Medical
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -55.5 M | -42 M | -26.9 M | -14.1 M | -42.2 M | -24.8 M | -13 M | -14.8 M | -8.4 M | -6.07 M | -6.74 M | -8.56 M | -6.67 M | -4.71 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.71 M | -55.5 M | -19.6 M |
Quarterly EBITDA AVITA Medical
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.73 M | -11.3 M | - | -13.5 M | -15.4 M | -17 M | - | -9.15 M | -11 M | -9.78 M | - | -5.62 M | -6.23 M | -9.32 M | - | -5.43 M | -4.36 M | -5.82 M | -5.5 M | -10 M | -5.26 M | -10 M | -10.5 M | -3.59 M | -7.49 M | -6.68 M | -6.3 M | -5.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.59 M | -17 M | -8.46 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
254 M | - | - | $ 17.2 B |  USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
-57.8 M | $ 21.04 | 0.86 % | $ 3.01 B | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.5 | 1.74 % | $ 121 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 9.4 | 1.08 % | $ 675 M |  Israel |
 |
Boston Scientific Corporation
BSX
|
3.87 B | $ 95.35 | -0.69 % | $ 140 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
421 M | $ 302.99 | -0.5 % | $ 8.55 B | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 47.11 | -0.84 % | $ 7.02 K | USA |
 |
Electromed
ELMD
|
10.7 M | $ 29.12 | 1.01 % | $ 246 M | USA |
 |
Abbott Laboratories
ABT
|
8.16 B | $ 125.29 | -0.39 % | $ 218 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.29 | 2.49 % | $ 123 M |  France |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
IRadimed Corporation
IRMD
|
22.8 M | $ 97.28 | -0.5 % | $ 1.23 B | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Zynex
ZYXI
|
8.89 M | - | - | $ 21.1 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.69 | -1.01 % | $ 1.17 B | Israel |
 |
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
753 M | $ 156.15 | -1.26 % | $ 11.7 B | USA |
 |
Accuray Incorporated
ARAY
|
14 M | $ 0.82 | 2.64 % | $ 84.3 M | USA |
 |
LivaNova PLC
LIVN
|
154 M | $ 61.53 | -1.2 % | $ 3.34 B |  Britain |
|
LENSAR
LNSR
|
-7.7 M | $ 11.63 | - | $ 134 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-18.8 M | $ 13.68 | 0.81 % | $ 370 M | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.56 | -0.22 % | $ 122 M | USA |
 |
AxoGen
AXGN
|
3.18 M | $ 32.73 | - | $ 1.45 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.14 | -0.87 % | $ 18.4 M | USA |
 |
CONMED Corporation
CNMD
|
217 M | $ 40.6 | -1.31 % | $ 1.25 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-15.9 M | $ 17.76 | -1.11 % | $ 410 M | USA |
 |
Myomo
MYO
|
-10.5 M | $ 0.91 | -1.58 % | $ 6.42 M | USA |
 |
Globus Medical
GMED
|
420 M | $ 87.31 | -0.68 % | $ 11.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 12.42 | -2.05 % | $ 956 M | USA |